My Bibliography

select

Dombrowski JC, Donnell D, Grabow C, Cohen SE, Cannon CA, Brown CE, Buchbinder SP, Celum C, Luetkemeyer AF. Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections. Clin Infect Dis. 2026 Feb 9;82(1):177-184. doi: 10.1093/cid/ciae527. PubMed PMID: 39478321.

select

Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, Sawant S, Zhang L, Mielke D, Khuzwayo S, Omar FL, Stanfield-Oakley S, Keyes T, Dunn B, Goodman D, Fong Y, Benkeser D, Zou R, Hural J, Hyrien O, Juraska M, Luedtke A, van der Laan L, Giorgi EE, Magaret C, Carpp LN, Pattacini L, van de Kerkhof T, Korber B, Willems W, Fisher LH, Schuitemaker H, Swann E, Kublin JG, Pau MG, Buchbinder S, Tomaka F, Nijs S, Lavreys L, Gelderblom HC, Corey L, Mngadi K, Gray GE, Borducchi E, Hendriks J, Seaton KE, Zolla-Pazner S, Barouch DH, Ferrari G, De Rosa SC, McElrath MJ, Andersen-Nissen E, Stieh DJ, Tomaras GD, Gilbert PB. Corrigendum to 'Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study'. EBioMedicine 2024;108: 105320. EBioMedicine. 2025 Sep;119:105874. doi: 10.1016/j.ebiom.2025.105874. Epub 2025 Aug 23. PubMed PMID: 40850015; PubMed Central PMCID: PMC12789700.

select

Landovitz RJ, Molina JM, Buchbinder SP. Preexposure Prophylaxis for HIV: Updated Recommendations From the 2024 International Antiviral Society-USA Panel. JAMA. 2025 Aug 19;334(7):638-639. doi: 10.1001/jama.2025.11410. PubMed PMID: 40576995.

select

Luetkemeyer AF, Chew KW, Lacey S, Hughes MD, Harrison LJ, Daar ES, Eron J, Fletcher CV, Greninger AL, Hessinger D, Li JZ, Mailhot D, Wohl D, Chayakulkeeree M, Mendoza JLA, Elistratova P, Makinde O, Morgan G, Portsmouth S, Uehara T, Smith D, Currier JS. Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial. Clin Infect Dis. 2025 Jul 18;80(6):1235-1244. doi: 10.1093/cid/ciaf029. PubMed PMID: 39960062; PubMed Central PMCID: PMC12272848.

select

Mda P, Mngadi K, Zhang B, Burnham R, Juraska M, Hyrien O, Garrett N, Dubula T, Toni S, Joseph S, Kotze P, Buchbinder S, Takalani A, Tomaka F, Luedtke A, Willems W, Swann E, Hutter J, Gelderblom H, McElrath MJ, Lavreys L, Stranix-Chibanda L, Roxby AC, Bekker LG, Gray GE. Pregnancy and contraceptive use among participants of childbearing potential in the HVTN 705 HIV vaccine trial in Southern Africa. Front Reprod Health. 2025;7:1565933. doi: 10.3389/frph.2025.1565933. eCollection 2025. PubMed PMID: 40556953; PubMed Central PMCID: PMC12185537.

select

Wilson EC, Myers J, Muñoz Acosta G, Sicro S, Schaeffer E, Alleyne CD, Diaz A, Walker N, Vinson J, Buchbinder S, Scott H, Liu A. Implementation Barriers and Facilitators in a Pilot Long-Acting HIV Treatment Intervention for Trans Women Living with HIV in San Francisco. AIDS Patient Care STDS. 2025 Jul;39(7):257-265. doi: 10.1089/apc.2024.0259. Epub 2025 Jun 6. PubMed PMID: 40474770.

select

Fichtenbaum CJ, Malvestutto CD, Watanabe MG, Davies Smith E, Ribaudo HJ, McCallum S, Fitch KV, Currier JS, Diggs MR, Chu SM, Aberg JA, Lu MT, Valencia J, Gómez-Ayerbe C, Brar I, Valdez Madruga J, Bloomfield GS, Douglas PS, Zanni MV, Grinspoon SK. Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis. Lancet HIV. 2025 Jul;12(7):e496-e505. doi: 10.1016/S2352-3018(25)00043-8. Epub 2025 Jun 4. PubMed PMID: 40482662; PubMed Central PMCID: PMC12244172.

select

Seaton KE, Paez CA, Yu C, Karuna ST, Gamble T, Miner MD, Heptinstall J, Zhang L, Gao F, Yacovone M, Spiegel H, Dumond JB, Anderson M, Piwowar-Manning E, Dye B, Tindale I, Proulx-Burns L, Trahey M, Takuva S, Takalani A, Bailey VC, Kalams SA, Scott H, Mkhize NN, Weiner JA, Ackerman ME, McElrath MJ, Pensiero M, Barouch DH, Montefiori D, Tomaras GD, Corey L, Cohen MS, Huang Y, Mahomed S, Siegel M, Kelley CF. Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial. Lancet HIV. 2025 Jun;12(6):e405-e415. doi: 10.1016/S2352-3018(25)00012-8. PubMed PMID: 40441807; PubMed Central PMCID: PMC12266790.

select

Liu AY, Torres TS, Alleyne CD, Vinson J, Bojan K, Serrano PA, Oyedele T, Garcia A, Enriquez-Bruce E, Emmanuel P, Jones J, Muessig KE, Buchbinder SP, Sullivan P, Hightow-Weidman LB, Scott H. Developing a Novel Mobile App to Support HIV Testing and Pre-Exposure Prophylaxis Uptake Among Men Who Have Sex With Men: Formative and Technical Pilot Study. JMIR Hum Factors. 2025 May 29;12:e62830. doi: 10.2196/62830. PubMed PMID: 40440084; PubMed Central PMCID: PMC12163352.

select

Buchbinder SP, Liu AY. CROI 2025: global epidemiology and prevention of HIV and other sexually transmitted diseases. Top Antivir Med. 2025 May 21;33(2):508-535. Review. PubMed PMID: 40472386.

select

Spinelli MA, Heise MJ, Roman J, Bena J, Barry MP, Buchbinder SP, Scott HM. Sustained Effectiveness of Doxycycline Post-Exposure-Prophylaxis in a Large Sexual Health Clinic over 96 Weeks: An Interrupted Time Series Analysis. Clin Infect Dis. 2025 May 6;. doi: 10.1093/cid/ciaf234. [Epub ahead of print] PubMed PMID: 40327542.

select

Andrews LIB, Halloran ME, Neuzil KM, van der Laan L, Huang Y, Andriesen J, Patel M, Fisher LH, Janes H, Rouphael N, Walsh SR, Theodore DA, Tieu HV, Sobieszczyk M, El Sahly HM, Baden LR, Falsey AR, Campbell TB, Kelley CF, Healy CM, Immergluck L, Luft B, Hirsch I, de Bruyn G, Truyers C, Priddy F, Sumner KM, Flannery B, Follmann D, Gilbert PB. Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials. JAMA Netw Open. 2025 May 1;8(5):e2512763. doi: 10.1001/jamanetworkopen.2025.12763. PubMed PMID: 40434773; PubMed Central PMCID: PMC12120655.

select

Jatt LP, Mgodi NM, Buchbinder SP, Gray GE, Kublin JG. An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP - Essential or Irrelevant?. N Engl J Med. 2025 Apr 24;392(16):1561-1563. doi: 10.1056/NEJMp2415893. Epub 2025 Apr 19. PubMed PMID: 40260855.

select

Mantell JE, Bauman LJ, Bonett S, Buchbinder S, Hoffman S, Storholm ED, McCoy K, Rael CT, Cowan E, Gonzalez-Argoti T, Safa H, Scott H, Murtaugh KL, Wilson NL, Liu A. Innovation in Providing Equitable Pre-exposure Prophylaxis Services in the United States: Expanding Access in Nontraditional Settings. J Acquir Immune Defic Syndr. 2025 Apr 15;98(5S):e156-e169. doi: 10.1097/QAI.0000000000003610. PubMed PMID: 40163068; NIHMSID:NIHMS2100861.

select

Mukerji SS, Bachanová P, Park H, Rosen LV, Kashlan R, Kivisäkk P, Anderson AM, Chow FC, Wu K, Dastgheyb RM, Rubin LH, Tassiopoulos K, Parker RA, Hyle EP. Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers of Cognitive Decline in People With Human Immunodeficiency Virus. J Infect Dis. 2025 Apr 15;231(4):946-956. doi: 10.1093/infdis/jiae623. PubMed PMID: 39723835; PubMed Central PMCID: PMC11998551.

select

McCoy K, Mantell JE, Deiss R, Liu A, Bauman LJ, Bonner CP, Vinson J, Buchbinder S. Pre-Exposure Prophylaxis Awareness and Demand Creation: Overlooked Populations and Opportunities to Move Forward. J Acquir Immune Defic Syndr. 2025 Apr 15;98(5S):e170-e180. doi: 10.1097/QAI.0000000000003626. PubMed PMID: 40163069; PubMed Central PMCID: PMC12256081.

select

Rodriguez-Diaz CE, Jaramillo J, Santiago-Rivera Y, Harkness A, Cantos VD, Liu A, Buchbinder S, Saldana CS, Gonzalez K, Malavé-Rivera SM, Reyes N, Vinson J, Scott JY, Lanzi RG, Hidalgo B. Language Justice in Implementation Science: Experiences Working With Latinxs to End the HIV Epidemic. J Acquir Immune Defic Syndr. 2025 Apr 15;98(5S):e104-e110. doi: 10.1097/QAI.0000000000003630. PubMed PMID: 40163061; PubMed Central PMCID: PMC12558689.

select

Harrison L, Velasquez GE, Kempker RR, Imperial MZ, Nuermberger E, Dorman SE, Ignatius E, Granche J, Phillips PP, Furin J, Yang E, Foley C, Chiambah S, Rogers R, Van Grack A, Roa J, Shenje J, Nerette S, Kanyama C, Kyeyune RB, Mendoza-Ticona A, Murtaugh W, Foraida S, Goth M, Vernon A, Dooley KE, Savic RM. ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis. Res Sq. 2025 Mar 26;. doi: 10.21203/rs.3.rs-5931694/v1. PubMed PMID: 40195983; PubMed Central PMCID: PMC11975035.

select

Luetkemeyer AF, Donnell D, Cohen SE, Dombrowski JC, Grabow C, Haser G, Brown C, Cannon C, Malinski C, Perkins R, Nasser M, Lopez C, Suchland RJ, Vittinghoff E, Buchbinder SP, Scott H, Charlebois ED, Havlir DV, Soge OO, Celum C. Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension. Lancet Infect Dis. 2025 Aug;25(8):873-883. doi: 10.1016/S1473-3099(25)00085-4. Epub 2025 Mar 24. PubMed PMID: 40147465.

select

Gao F, Janes H, Buchbinder S, Donnell D. Active-Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo. Stat Med. 2025 Mar 15;44(6):e70022. doi: 10.1002/sim.70022. PubMed PMID: 40042432; PubMed Central PMCID: PMC12758560.

select

Kurbatova EV, Whitworth WC, Peddareddy LP, Phillips PPJ, Scott NA, Bryant KE, Dawson R, Cardoso SW, Samaneka W, Engle M, Waja Z, Sizemore E, Carr W, Dooley KE, Savic R, Swindells S, Chaisson RE, Dorman SE, Nahid P, Nguyen NV. Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes. Emerg Infect Dis. 2025 Mar;31(3):467-476. doi: 10.3201/eid3103.241634. PubMed PMID: 40023788; PubMed Central PMCID: PMC11878306.

select

Sankaran M, Glidden DV, Kohn RP, Nguyen TQ, Bacon O, Buchbinder SP, Gandhi M, Havlir DV, Liebi C, Luetkemeyer AF, Nguyen JQ, Roman J, Scott H, Torres TS, Cohen SE. Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends. JAMA Intern Med. 2025 Mar 1;185(3):266-272. doi: 10.1001/jamainternmed.2024.7178. PubMed PMID: 39761052; PubMed Central PMCID: PMC11877200.

select

Pahus MH, Zheng Y, Olefsky M, Gunst JD, Tebas P, Taiwo B, Søgaard OS, Peluso MJ, Lie Y, Reeves JD, Petropoulos CJ, Caskey M, Bar KJ. Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti-HIV-1 Antibodies. J Infect Dis. 2025 Feb 20;231(2):424-434. doi: 10.1093/infdis/jiae486. PubMed PMID: 39441137; PubMed Central PMCID: PMC11841631.

select

Magombedze G, Vendrame E, SenGupta D, Geleziunas R, Little S, Smith D, Walker B, Routy JP, Hecht FM, Chun TW, Sneller M, Li JZ, Deeks SG, Peluso MJ. Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment Interruption. J Infect Dis. 2025 Feb 20;231(2):e419-e428. doi: 10.1093/infdis/jiae551. PubMed PMID: 39513745; PubMed Central PMCID: PMC11841646.

select

Gandhi RT, Landovitz RJ, Sax PE, Smith DM, Springer SA, Günthard HF, Thompson MA, Bedimo RJ, Benson CA, Buchbinder SP, Crabtree-Ramirez BE, Del Rio C, Eaton EF, Eron JJ Jr, Hoy JF, Lehmann C, Molina JM, Jacobsen DM, Saag MS. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2025 Feb 18;333(7):609-628. doi: 10.1001/jama.2024.24543. PubMed PMID: 39616604.

select

Covington N, Luetkemeyer AF, Imperial MZ, Dawson R, Cramer Y, Rosenkranz S, Swindells S, Gelmanova I, Avihingsanon A, Arduino RC, Samaneka W, Dooley KE, Savic R, Podany AT, Haas DW. Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis. Pharmacogenet Genomics. 2025 Jun 1;35(4):140-144. doi: 10.1097/FPC.0000000000000562. Epub 2025 Feb 12. PubMed PMID: 39960813; PubMed Central PMCID: PMC12043259.

select

Biello KB, Mayer KH, Scott H, Valente PK, Hill-Rorie J, Buchbinder S, Ackah-Toffey L, Sullivan PS, Hightow-Weidman L, Liu AY. The Effects of MyChoices and LYNX Mobile Apps on HIV Testing and Pre-Exposure Prophylaxis Use by Young US Sexual Minority Men: Results From a National Randomized Controlled Trial. JMIR Public Health Surveill. 2025 Feb 5;11:e63428. doi: 10.2196/63428. PubMed PMID: 39908084; PubMed Central PMCID: PMC11840373.

select

Marks KM, Kang M, Umbleja T, Cox A, Vigil KJ, Ta NT, Omoz-Oarhe A, Perazzo H, Kosgei J, Hatlen T, Price J, Katsidzira L, Supparatpinyo K, Knowles K, Alston-Smith BL, Rathod P, Sherman KE. HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial. JAMA. 2025 Jan 28;333(4):295-306. doi: 10.1001/jama.2024.24490. PubMed PMID: 39616603; PubMed Central PMCID: PMC11610526.

select

Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 3;392(13):1261-1276. doi: 10.1056/NEJMoa2411858. Epub 2024 Nov 27. PubMed PMID: 39602624.

select

Barbehenn A, Shi L, Shao J, Hoh R, Hartig HM, Pae V, Sarvadhavabhatla S, Donaire S, Sheikhzadeh C, Milush J, Laird GM, Mathias M, Ritter K, Peluso MJ, Martin J, Hecht F, Pilcher C, Cohen SE, Buchbinder S, Havlir D, Gandhi M, Henrich TJ, Hatano H, Wang J, Deeks SG, Lee SA. Rapid biphasic decay of intact and defective HIV DNA reservoir during acute treated HIV disease. Nat Commun. 2024 Nov 18;15(1):9966. doi: 10.1038/s41467-024-54116-1. PubMed PMID: 39557853; PubMed Central PMCID: PMC11574060.

select

Chang VK, Imperial MZ, Phillips PPJ, Velásquez GE, Nahid P, Vernon A, Kurbatova EV, Swindells S, Chaisson RE, Dorman SE, Johnson JL, Weiner M, Jindani A, Harrison T, Sizemore EE, Whitworth W, Carr W, Bryant KE, Burton D, Dooley KE, Engle M, Nsubuga P, Diacon AH, Nhung NV, Dawson R, Savic RM. Risk-stratified treatment for drug-susceptible pulmonary tuberculosis. Nat Commun. 2024 Oct 30;15(1):9400. doi: 10.1038/s41467-024-53273-7. PubMed PMID: 39477924; PubMed Central PMCID: PMC11526018.

select

Podany AT, Cramer Y, Imperial M, Rosenkranz SL, Avihingsanon A, Arduino R, Samaneka W, Gelmanova I, Savic R, Swindells S, Dawson R, Luetkemeyer AF. Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2024 Oct 15;79(4):983-989. doi: 10.1093/cid/ciae183. PubMed PMID: 38568956; PubMed Central PMCID: PMC11478809.

select

Henrich TJ, Bosch RJ, Godfrey C, Mar H, Nair A, Keefer M, Fichtenbaum C, Moisi D, Clagett B, Buck AM, Deitchman AN, Aweeka F, Li JZ, Kuritzkes DR, Lederman MM, Hsue PY, Deeks SG. Sirolimus reduces T cell cycling, immune checkpoint marker expression, and HIV-1 DNA in people with HIV. Cell Rep Med. 2024 Oct 15;5(10):101745. doi: 10.1016/j.xcrm.2024.101745. Epub 2024 Sep 24. PubMed PMID: 39321793; PubMed Central PMCID: PMC11513808.

select

Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, Sawant S, Zhang L, Mielke D, Khuzwayo S, Omar FL, Stanfield-Oakley S, Keyes T, Dunn B, Goodman D, Fong Y, Benkeser D, Zou R, Hural J, Hyrien O, Juraska M, Luedtke A, van der Laan L, Giorgi EE, Magaret C, Carpp LN, Pattacini L, van de Kerkhof T, Korber B, Willems W, Fisher LH, Schuitemaker H, Swann E, Kublin JG, Pau MG, Buchbinder S, Tomaka F, Nijs S, Lavreys L, Gelderblom HC, Corey L, Mngadi K, Gray GE, Borducchi E, Hendriks J, Seaton KE, Zolla-Pazner S, Barouch DH, Ferrari G, De Rosa SC, McElrath MJ, Andersen-Nissen E, Stieh DJ, Tomaras GD, Gilbert PB. Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study. EBioMedicine. 2024 Oct;108:105320. doi: 10.1016/j.ebiom.2024.105320. Epub 2024 Sep 4. PubMed PMID: 39236556; PubMed Central PMCID: PMC11404224.

select

Velloza J, Liu AY, Katz AWK, van der Straten A, Siegler AJ, Scott H, Wilde G, Lockard A, Christie RH, Buchbinder SP. Acceptability of an automated directly observed therapy (DOT) application for PrEP adherence support among young men who have sex with men: a qualitative exploration. AIDS Care. 2024 Nov;36(11):1704-1718. doi: 10.1080/09540121.2024.2397133. Epub 2024 Sep 2. PubMed PMID: 39222964; PubMed Central PMCID: PMC11511627.

select

Dubé K, Villa TJ, Freshwater W, Mauk B, Rid A, Peluso MJ. Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk. J Virus Erad. 2024 Sep;10(3):100386. doi: 10.1016/j.jve.2024.100386. eCollection 2024 Sep. PubMed PMID: 39364082; PubMed Central PMCID: PMC11447310.

select

Barbehenn A, Shi L, Shao J, Hoh R, Hartig HM, Pae V, Sarvadhavabhatla S, Donaire S, Sheikhzadeh C, Milush J, Laird GM, Mathias M, Ritter K, Peluso MJ, Martin J, Hecht F, Pilcher C, Cohen SE, Buchbinder S, Havlir D, Gandhi M, Henrich TJ, Hatano H, Wang J, Deeks SG, Lee SA. Rapid Biphasic Decay of Intact and Defective HIV DNA Reservoir During Acute Treated HIV Disease. medRxiv. 2024 Aug 22;. doi: 10.1101/2024.03.27.24304867. PubMed PMID: 38585951; PubMed Central PMCID: PMC10996734.

select

Chirenje ZM, Laher F, Dintwe O, Muyoyeta M, deCamp AC, He Z, Grunenberg N, Laher Omar F, Seaton KE, Polakowski L, Woodward Davis AS, Maganga L, Baden LR, Mayer K, Kalams S, Keefer M, Edupuganti S, Rodriguez B, Frank I, Scott H, Stranix-Chibanda L, Gurunathan S, Koutsoukos M, Van Der Meeren O, DiazGranados CA, Paez C, Andersen-Nissen E, Kublin J, Corey L, Ferrari G, Tomaras G, McElrath MJ. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. J Infect Dis. 2024 Aug 16;230(2):e405-e415. doi: 10.1093/infdis/jiad434. PubMed PMID: 37795976; PubMed Central PMCID: PMC11326849.

select

Kalams SA, Felber BK, Mullins JI, Scott HM, Allen MA, De Rosa SC, Heptinstall J, Tomaras GD, Hu J, DeCamp AC, Rosati M, Bear J, Pensiero MN, Eldridge J, Egan MA, Hannaman D, McElrath MJ, Pavlakis GN. Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119. JCI Insight. 2024 Aug 1;9(18). doi: 10.1172/jci.insight.180819. PubMed PMID: 39088271; PubMed Central PMCID: PMC11466283.

select

Gray GE, Mngadi K, Lavreys L, Nijs S, Gilbert PB, Hural J, Hyrien O, Juraska M, Luedtke A, Mann P, McElrath MJ, Odhiambo JA, Stieh DJ, van Duijn J, Takalani AN, Willems W, Tapley A, Tomaras GD, Van Hoof J, Schuitemaker H, Swann E, Barouch DH, Kublin JG, Corey L, Pau MG, Buchbinder S, Tomaka F. Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Infect Dis. 2024 Nov;24(11):1201-1212. doi: 10.1016/S1473-3099(24)00358-X. Epub 2024 Jul 19. PubMed PMID: 39038477; PubMed Central PMCID: PMC11512672.

select

Liu AY, Buchbinder SP. CROI 2024: Global Epidemiology and Prevention of HIV and Other Sexually Transmitted Diseases. Top Antivir Med. 2024 Jul 17;32(3):447-482. PubMed PMID: 39142289; PubMed Central PMCID: PMC11293602.

select

Beyrer C, Tomaras GD, Gelderblom HC, Gray GE, Janes HE, Bekker LG, Millett G, Pantaleo G, Buchbinder S, Corey L. Is HIV epidemic control by 2030 realistic?. Lancet HIV. 2024 Jul;11(7):e489-e494. doi: 10.1016/S2352-3018(24)00098-5. Review. PubMed PMID: 38925732; PubMed Central PMCID: PMC11416730.

select

Martinson T, Montoya R, Moreira C, Kuncze K, Sassaman K, Heise MJ, Glidden DV, Amico KR, Arnold EA, Buchbinder SP, Ewart LD, Carrico A, Wang G, Okochi H, Scott HM, Gandhi M, Spinelli MA. Point-of-care urine tenofovir test predicts future HIV preexposure prophylaxis discontinuation among young users. AIDS. 2024 Sep 1;38(11):1671-1676. doi: 10.1097/QAD.0000000000003962. Epub 2024 Jun 20. PubMed PMID: 38905507; PubMed Central PMCID: PMC11293961.

select

Ngo HX, Xu AY, Velásquez GE, Zhang N, Chang VK, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Weiner M, Dooley KE, Engle M, Dorman SE, Nahid P, Swindells S, Chaisson RE, Nsubuga P, Lourens M, Dawson R, Savic RM. Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis. Clin Infect Dis. 2024 Jun 14;78(6):1680-1689. doi: 10.1093/cid/ciae119. PubMed PMID: 38462673; PubMed Central PMCID: PMC11175687.

select

Giguere R, Balán IC, Kutner BA, Choi SK, Tingler R, Johnson S, Macagna N, Webster J, Liu A, Chariyalertsak S, Hoesley C, Gonzales P, Ho K, Kayange N, Palanee-Phillips T, Brown E, Zemanek J, Jacobson CE, Doncel GF, Piper J, Bauermeister JA. History of Rectal Product Use and Country of Residence Influence Preference for Rectal Microbicide Dosage Forms Among Young Sexual and Gender Minorities: A Multi-country Trial Comparing Placebo Douche, Suppository, and Insert Products. AIDS Behav. 2024 Aug;28(8):2577-2589. doi: 10.1007/s10461-024-04360-9. Epub 2024 May 13. PubMed PMID: 38740628; PubMed Central PMCID: PMC11480948.

select

Fisher LH, Kee JJ, Liu A, Espinosa CM, Randhawa AK, Ludwig J, Magaret CA, Robinson ST, Gilbert PB, Hyrien O, Kublin JG, Rouphael N, Falsey AR, Sobieszczyk ME, El Sahly HM, Grinsztejn B, Gray GE, Kotloff KL, Gay CL, Leav B, Hirsch I, Struyf F, Dunkle LM, Neuzil KM, Corey L, Huang Y, Goepfert PA, Walsh SR, Baden LR, Janes H. SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials. JAMA Netw Open. 2024 May 1;7(5):e2412835. doi: 10.1001/jamanetworkopen.2024.12835. PubMed PMID: 38780941; PubMed Central PMCID: PMC11117088.

select

Feelemyer J, Duncan DT, Akhidenor N, Mazumdar M, Irvine NM, Scheidell JD, Brewer RA, Turpin RE, Hucks-Ortiz C, Dyer TV, Cleland CM, Mayer KH, Khan MR. Police Harassment and Psychiatric, Sexual, and Substance Use Risk Among Black Sexual Minority Men and Black Transgender Women in the HIV Prevention Trials 061 Cohort. J Racial Ethn Health Disparities. 2025 Apr;12(2):692-702. doi: 10.1007/s40615-024-01909-1. Epub 2024 Apr 12. PubMed PMID: 38609695; PubMed Central PMCID: PMC11470103.

select

Liu AY, Alleyne CD, Doblecki-Lewis S, Koester KA, Gonzalez R, Vinson J, Scott H, Buchbinder S, Torres TS. Adapting mHealth Interventions (PrEPmate and DOT Diary) to Support PrEP Retention in Care and Adherence Among English and Spanish-Speaking Men Who Have Sex With Men and Transgender Women in the United States: Formative Work and Pilot Randomized Trial. JMIR Form Res. 2024 Mar 27;8:e54073. doi: 10.2196/54073. PubMed PMID: 38536232; PubMed Central PMCID: PMC11007601.

select

Bauermeister J, Lin W, Tingler R, Liu A, Chariyalertsak S, Hoesley C, Gonzales P, Ho K, Kayange N, Phillips TP, Johnson S, Brown E, Zemanek J, Jacobson CE, Doncel GF, Piper J. A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN-035. J Int AIDS Soc. 2024 Mar;27(3):e26219. doi: 10.1002/jia2.26219. PubMed PMID: 38494656; PubMed Central PMCID: PMC10945032.

select

Li JZ, Melberg M, Kittilson A, Abdel-Mohsen M, Li Y, Aga E, Bosch RJ, Wonderlich ER, Kinslow J, Giron LB, Di Germanio C, Pilkinton M, MacLaren L, Keefer M, Fox L, Barr L, Acosta E, Ananworanich J, Coombs R, Mellors J, Deeks S, Gandhi RT, Busch M, Landay A, Macatangay B, Smith DM. Predictors of HIV rebound differ by timing of antiretroviral therapy initiation. JCI Insight. 2024 Feb 8;9(3). doi: 10.1172/jci.insight.173864. PubMed PMID: 38329130; PubMed Central PMCID: PMC10967395.